ETF Investors Pour $500M Into a Market at a Technical Extreme

BlackRock's iShares MSCI World ETF (URTH) attracts $500M in a week but RSI soars to 94.6. Upcoming MSCI rebalance, free-float changes, and political headwinds test the fund's high-concentration tech portfolio.

The iShares MSCI World ETF (URTH) is pulling in capital at a remarkable clip while simultaneously flashing some of the most aggressive technical signals in its recent history. In a single trading week in mid-May, the fund absorbed nearly $500 million in fresh money, pushing assets under management to roughly $7.96 billion. Yet at the same time, the relative strength index has surged to 94.6 — a level that screams overbought and has historically preceded a consolidation. The fund closed at a new 52-week high of $202.74 before pulling back to $200.50.

That tension between strong inflows and an overheated tape is about to be tested by a thicket of structural changes. On May 29, MSCI’s semiannual index review takes effect, forcing BlackRock to buy and sell securities to keep URTH’s physical replication in line. The three largest additions to the MSCI World by full market capitalisation are all US stocks: Medline A, MasTec and TechnipFMC. In the broader MSCI ACWI, 49 names enter and 101 are deleted. A day later, on June 1, a revised free-float methodology kicks in, reclassifying certain equity swaps and adjusting thresholds for insurance companies in select European markets.

The index changes come as URTH’s portfolio remains heavily concentrated in mega-cap US technology. Nvidia alone accounts for roughly 6% of the fund, with a market value of $478.2 million. Apple follows at $385.6 million, Microsoft at $261.1 million, Amazon at $231.9 million and Alphabet at $202.5 million. Technology stocks as a sector represent about 29% of the portfolio, while US-listed equities in total make up over 70%. The result: a price-to-book ratio of nearly 4.0 and a year-to-date gain of roughly 8%.

That dominance is drawing competitive heat on costs. Invesco has slashed the total expense ratio on its rival MSCI World product to 0.05%, with UBS and BNP Paribas following suit. BlackRock has held URTH steady at 0.24% — a 19-basis-point gap to the cheapest competitor. Yet investors have not fled. The fund’s Morningstar gold rating and a tracking difference of just 0.02% have kept net inflows robust; recently they stood at $770 million. High liquidity and precise index replication appear to trump price for large institutional allocators.

Political headwinds are also building. US pharma tariffs are scheduled to take effect at the end of July, hitting patented drugs from the European Union, Japan, South Korea and Switzerland at 15%, and British goods at 10%. Companies without existing US price agreements face a surcharge of 100%. This directly threatens the healthcare sector, which makes up about 10% of URTH’s holdings. Separately, Washington is pursuing policies that favour American products, a protectionist tilt that could weigh on the multinational giants that dominate the index.

A potential SpaceX initial public offering adds a wild card. The rocket company is valued at roughly $75 billion, and Nasdaq has already adjusted its listing rules — eliminating the 10% minimum free-float requirement and slashing the waiting period for index inclusion from three months to 15 trading days. A SpaceX entry into the MSCI World would trigger billions in index-driven capital flows and further inflate the already heavy US weighting.

On the trading front, volume has shown a curious divergence. Even as the share price climbed to within striking distance of its annual peak, daily turnover occasionally slipped to around 338,000 units. That thin liquidity beneath a technical extreme leaves the fund vulnerable to sharp reversals.

With the index overhaul imminent and the tariff deadline in late July, the next two months present the clearest test of whether the iShares MSCI World ETF can sustain its record-breaking run. For now, the money keeps coming — but the risks keep stacking.